- Home
- TNGX vs LOCO Comparison
TNGX vs LOCO Comparison
Compare TNGX & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- LOCO
- Stock Information
- Founded
- TNGX 2014
- LOCO 1980
- Country
- TNGX United States
- LOCO United States
- Employees
- TNGX N/A
- LOCO N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- LOCO Restaurants
- Sector
- TNGX Health Care
- LOCO Consumer Discretionary
- Exchange
- TNGX Nasdaq
- LOCO Nasdaq
- Market Cap
- TNGX 351.2M
- LOCO 331.5M
- IPO Year
- TNGX N/A
- LOCO 2014
- Fundamental
- Price
- TNGX $5.63
- LOCO $11.47
- Analyst Decision
- TNGX Strong Buy
- LOCO Buy
- Analyst Count
- TNGX 6
- LOCO 3
- Target Price
- TNGX $12.20
- LOCO $15.50
- AVG Volume (30 Days)
- TNGX 3.3M
- LOCO 401.2K
- Earning Date
- TNGX 08-06-2025
- LOCO 07-31-2025
- Dividend Yield
- TNGX N/A
- LOCO N/A
- EPS Growth
- TNGX N/A
- LOCO 6.54
- EPS
- TNGX N/A
- LOCO 0.86
- Revenue
- TNGX $40,990,000.00
- LOCO $476,032,000.00
- Revenue This Year
- TNGX N/A
- LOCO $6.28
- Revenue Next Year
- TNGX N/A
- LOCO $1.14
- P/E Ratio
- TNGX N/A
- LOCO $13.34
- Revenue Growth
- TNGX 10.09
- LOCO 1.22
- 52 Week Low
- TNGX $1.03
- LOCO $8.29
- 52 Week High
- TNGX $12.02
- LOCO $14.25
- Technical
- Relative Strength Index (RSI)
- TNGX 78.55
- LOCO 63.76
- Support Level
- TNGX $4.80
- LOCO $10.91
- Resistance Level
- TNGX $5.96
- LOCO $11.09
- Average True Range (ATR)
- TNGX 0.51
- LOCO 0.39
- MACD
- TNGX -0.02
- LOCO 0.03
- Stochastic Oscillator
- TNGX 92.95
- LOCO 86.23
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.